Mirum Pharmaceuticals (MIRM) Revenue (2021 - 2026)

Mirum Pharmaceuticals' Revenue history runs 6 years deep, the most recent figure standing at $159.9 million for Q1 2026.

• On a quarterly basis, Revenue rose 43.28% year-over-year to $159.9 million in Q1 2026; TTM through Mar 2026 was $569.6 million, a 50.19% increase from a year earlier, with the FY2025 full-year figure at $521.3 million, up 54.74% from the prior year.
• Revenue rose to $159.9 million in Q1 2026 per MIRM's latest filing, from $148.9 million in the prior quarter.
• Across five years, Revenue topped out at $159.9 million in Q1 2026 and bottomed at $12.9 million in Q1 2022.
• The 5-year median for Revenue is $69.6 million (2023), against an average of $75.4 million.
• Across the five-year window, Revenue soared 789.29% in 2022 and jumped 42.93% in 2024, its largest moves.
• Year by year, Revenue stood at $27.9 million in 2022, then soared by 149.24% to $69.6 million in 2023, then soared by 42.93% to $99.4 million in 2024, then surged by 49.81% to $148.9 million in 2025, then climbed by 7.35% to $159.9 million in 2026.
• Per Business Quant, the three latest MIRM Revenue figures stand at $159.9 million (Q1 2026), $148.9 million (Q4 2025), and $133.0 million (Q3 2025).